Evicenter
MarkdownP&T meetings
Hibsago (bepirovirsen)

Chronic hepatitis B virus infection in adults without cirrhosis

Also known as GSK3228836
Manufacturer
GSK
Last updated
190 sources

Section 6 of 6

References

190 sources

  1. Agarwal et al. (2024) (opens in a new tab)
  2. Anderson et al. (2025) (opens in a new tab)
  3. Bixler et al. (2019) (opens in a new tab)
  4. Bixler et al. (2023) (opens in a new tab)
  5. Bouquet et al. (2026) (opens in a new tab)
  6. Buti et al. (2024) (opens in a new tab)
  7. Buti et al. (2025) (opens in a new tab)
  8. CDA-AMC bepirovirsen reimbursement review (2026) (opens in a new tab)
  9. CDC Clinical Care of Hepatitis B (2025) (opens in a new tab)
  10. CDC Clinical Overview of Hepatitis B (2025) (opens in a new tab)
  11. CDC Clinical Signs and Symptoms of Hepatitis B (2025) (opens in a new tab)
  12. CDC Clinical Testing and Diagnosis for Hepatitis B (2026) (opens in a new tab)
  13. CDC guidelines and quality measures (2026) (opens in a new tab)
  14. CDC Viral Hepatitis Surveillance Report (2025) (opens in a new tab)
  15. CDC Viral Hepatitis Surveillance Report national profile (2025) (opens in a new tab)
  16. Chen et al. (2006) (opens in a new tab)
  17. Cheng et al. (2026) (opens in a new tab)
  18. Clinical Pharmacology in Drug Development (2025) (opens in a new tab)
  19. ClinicalTrials.gov NCT02981602 (opens in a new tab)
  20. ClinicalTrials.gov NCT02981602 (opens in a new tab)
  21. ClinicalTrials.gov NCT04449029 (opens in a new tab)
  22. ClinicalTrials.gov NCT04449029 (opens in a new tab)
  23. ClinicalTrials.gov NCT04544956 (opens in a new tab)
  24. ClinicalTrials.gov NCT04544956 (opens in a new tab)
  25. ClinicalTrials.gov NCT04676724 (opens in a new tab)
  26. ClinicalTrials.gov NCT04676724 (opens in a new tab)
  27. ClinicalTrials.gov NCT04954859 (opens in a new tab)
  28. ClinicalTrials.gov NCT04971928 (opens in a new tab)
  29. ClinicalTrials.gov NCT05276297 (opens in a new tab)
  30. ClinicalTrials.gov NCT05276297 (opens in a new tab)
  31. ClinicalTrials.gov NCT05630807 (opens in a new tab)
  32. ClinicalTrials.gov NCT05630820 (opens in a new tab)
  33. ClinicalTrials.gov NCT06058390 (opens in a new tab)
  34. ClinicalTrials.gov NCT06058390 (opens in a new tab)
  35. ClinicalTrials.gov NCT06422767 (opens in a new tab)
  36. ClinicalTrials.gov NCT06422767 (opens in a new tab)
  37. ClinicalTrials.gov NCT06497504 (opens in a new tab)
  38. ClinicalTrials.gov NCT06537414 (opens in a new tab)
  39. ClinicalTrials.gov NCT07168356 (opens in a new tab)
  40. CMS (2025) (opens in a new tab)
  41. CMS 2027 Adult Core Set (opens in a new tab)
  42. Congly et al. (2024) (opens in a new tab)
  43. Conners et al. (2023) (opens in a new tab)
  44. Cremer et al. (2023) (opens in a new tab)
  45. Delahaye et al. (2026) (opens in a new tab)
  46. Dongelmans et al. (2026) (opens in a new tab)
  47. Drysdale et al. (2026) (opens in a new tab)
  48. EASL (2025) (opens in a new tab)
  49. EMA paediatric investigation plan decision P/0254/2022 (2022) (opens in a new tab)
  50. Ermler et al. (2026) (opens in a new tab)
  51. EU Clinical Trials Information System 2023-504238-23-00 (opens in a new tab)
  52. EU Clinical Trials Information System 2023-504239-41-00 (opens in a new tab)
  53. EU Clinical Trials Register 2021-005139-22 (opens in a new tab)
  54. EU Clinical Trials Register 2022-002268-53 (opens in a new tab)
  55. FDA guidance on chronic hepatitis B drug development (2022) (opens in a new tab)
  56. FDA Hibsago approval announcement (2026) (opens in a new tab)
  57. FDA Novel Drug Approvals for 2026 (2026) (opens in a new tab)
  58. Fierce Pharma (2026) (opens in a new tab)
  59. Freeland et al. (2021) (opens in a new tab)
  60. Freeland et al. (2024) (opens in a new tab)
  61. Fu et al. (2025) (opens in a new tab)
  62. Gadano et al. (2023) (opens in a new tab)
  63. Gane et al. (2025) (opens in a new tab)
  64. Gane et al. (2026a) (opens in a new tab)
  65. Gane et al. (2026b) (opens in a new tab)
  66. GBD 2019 Hepatitis B Collaborators (2022) (opens in a new tab)
  67. Ghany et al. (2023) (opens in a new tab)
  68. Ghany et al. (2026) (opens in a new tab)
  69. Gilead Sciences (2024) (opens in a new tab)
  70. Gish et al. (2024) (opens in a new tab)
  71. GSK 205873 protocol (2024) (opens in a new tab)
  72. GSK 209348 protocol (2021) (opens in a new tab)
  73. GSK 209668 protocol (2021) (opens in a new tab)
  74. GSK 209668 statistical analysis plan (2022) (opens in a new tab)
  75. GSK 212602 protocol (2021) (opens in a new tab)
  76. GSK 219239 protocol (2023) (opens in a new tab)
  77. GSK FY2023 results slides (2024) (opens in a new tab)
  78. GSK FY2025 pipeline assets and clinical trials appendix (2026) (opens in a new tab)
  79. GSK press release, AASLD 2025 (2025) (opens in a new tab)
  80. GSK press release, B-Clear results (2022) (opens in a new tab)
  81. GSK press release, B-Well results (2026) (opens in a new tab)
  82. GSK press release, B-Well topline (2026) (opens in a new tab)
  83. GSK press release, China acceptance (2026) (opens in a new tab)
  84. GSK press release, EMA acceptance (2026) (opens in a new tab)
  85. GSK press release, Fast Track designation (2024) (opens in a new tab)
  86. GSK press release, FDA priority review (2026) (opens in a new tab)
  87. GSK press release, Hibsago Japan approval (2026) (opens in a new tab)
  88. GSK press release, Hibsago US approval (2026) (opens in a new tab)
  89. GSK press release, Japan acceptance (2026) (opens in a new tab)
  90. GSK press release, SBP Group collaboration (2026) (opens in a new tab)
  91. GSK press release, SENKU designation (2024) (opens in a new tab)
  92. GSK Q1 2026 results (2026) (opens in a new tab)
  93. GSK Q2 2026 results (2026) (opens in a new tab)
  94. Han et al. (2022) (opens in a new tab)
  95. Han et al. (2025) (opens in a new tab)
  96. HHS Viral Hepatitis National Strategic Plan (2020) (opens in a new tab)
  97. Hibsago prescribing information (2026) (opens in a new tab)
  98. Hirode et al. (2022) (opens in a new tab)
  99. Hoofnagle (2022) (opens in a new tab)
  100. Hou et al. (2024) (opens in a new tab)
  101. Hou et al. (2026a) (opens in a new tab)
  102. Hou et al. (2026b) (opens in a new tab)
  103. Hui et al. (2025) (opens in a new tab)
  104. Hutton et al. (2022) (opens in a new tab)
  105. Iannacone and Guidotti (2022) (opens in a new tab)
  106. Iloeje et al. (2006) (opens in a new tab)
  107. Ionis ISIS 505358-CS3 protocol (2019) (opens in a new tab)
  108. Ionis press release, GSK license (2019) (opens in a new tab)
  109. Ionis press release, Hibsago US approval (2026) (opens in a new tab)
  110. Ionis press release, phase 3 start (2023) (opens in a new tab)
  111. Jeng et al. (2026) (opens in a new tab)
  112. Joshi et al. (2026) (opens in a new tab)
  113. Kaushik et al. (2024) (opens in a new tab)
  114. KEGG DRUG D12615 (opens in a new tab)
  115. Kim et al. (2014) (opens in a new tab)
  116. Kim et al. (2019) (opens in a new tab)
  117. Kudaravalli et al. (2024) (opens in a new tab)
  118. Lai et al. (2025) (opens in a new tab)
  119. Lau et al. (2005) (opens in a new tab)
  120. Lee et al. (2024) (opens in a new tab)
  121. Lens (2023) (opens in a new tab)
  122. Lens (2026) (opens in a new tab)
  123. Levy et al. (2008) (opens in a new tab)
  124. Lim et al. (2020) (opens in a new tab)
  125. Lim et al. (2025a) (opens in a new tab)
  126. Lim et al. (2025b) (opens in a new tab)
  127. Lok (2026) (opens in a new tab)
  128. Lok et al. (2017) (opens in a new tab)
  129. Low et al. (2025) (opens in a new tab)
  130. Ly et al. (2022) (opens in a new tab)
  131. Mak et al. (2023) (opens in a new tab)
  132. Marcellin et al. (2004) (opens in a new tab)
  133. Mathematica (2025) (opens in a new tab)
  134. MHLW Chuikyo DPC high-cost new drugs (2026) (opens in a new tab)
  135. MHLW Chuikyo new drug price listing (2026) (opens in a new tab)
  136. Nguyen et al. (2019) (opens in a new tab)
  137. Nguyen et al. (2020) (opens in a new tab)
  138. Nguyen et al. (2022) (opens in a new tab)
  139. NICE ID6608 (opens in a new tab)
  140. NIHR Innovation Observatory (2025) (opens in a new tab)
  141. Noormohamed et al. (2024) (opens in a new tab)
  142. ODPHP Healthy People 2030 IID-13 (opens in a new tab)
  143. ODPHP Healthy People 2030 IID-15 (opens in a new tab)
  144. Pan et al. (2026) (opens in a new tab)
  145. Papatheodoridis et al. (2026) (opens in a new tab)
  146. Pharmaphorum (2026) (opens in a new tab)
  147. Pirzada et al. (2026) (opens in a new tab)
  148. Polaris Observatory Collaborators (2023) (opens in a new tab)
  149. Razavi-Shearer et al. (2023a) (opens in a new tab)
  150. Razavi-Shearer et al. (2023b) (opens in a new tab)
  151. Razavi-Shearer et al. (2026) (opens in a new tab)
  152. Revill et al. (2019) (opens in a new tab)
  153. Roberts et al. (2021) (opens in a new tab)
  154. Salem et al. (2026) (opens in a new tab)
  155. Sbarigia et al. (2020) (opens in a new tab)
  156. Smith-Palmer et al. (2020) (opens in a new tab)
  157. Song et al. (2021) (opens in a new tab)
  158. Spencer-Dene et al. (2023) (opens in a new tab)
  159. Terrault et al. (2018) (opens in a new tab)
  160. Toy et al. (2022a) (opens in a new tab)
  161. Toy et al. (2022b) (opens in a new tab)
  162. Toy et al. (2025) (opens in a new tab)
  163. US Preventive Services Task Force (2020) (opens in a new tab)
  164. Vaillant (2023) (opens in a new tab)
  165. Vir Biotechnology press release (2025) (opens in a new tab)
  166. Wang et al. (2026) (opens in a new tab)
  167. WHO Global hepatitis report (2026) (opens in a new tab)
  168. WHO hepatitis B fact sheet (2026) (opens in a new tab)
  169. WHO hepatitis B guidelines (2024) (opens in a new tab)
  170. Wong et al. (2021) (opens in a new tab)
  171. Wong et al. (2026a) (opens in a new tab)
  172. Wong et al. (2026b) (opens in a new tab)
  173. Wong et al. (2026c) (opens in a new tab)
  174. Yang et al. (2023) (opens in a new tab)
  175. Yao et al. (2026) (opens in a new tab)
  176. Ye et al. (2022) (opens in a new tab)
  177. Yeo et al. (2019) (opens in a new tab)
  178. Yilmaz et al. (2026) (opens in a new tab)
  179. Younossi et al. (2018) (opens in a new tab)
  180. Youssef et al. (2024) (opens in a new tab)
  181. Youssef et al. (2026) (opens in a new tab)
  182. Yuen et al. (2021) (opens in a new tab)
  183. Yuen et al. (2022) (opens in a new tab)
  184. Yuen et al. (2023a) (opens in a new tab)
  185. Yuen et al. (2023b) (opens in a new tab)
  186. Yuen et al. (2024) (opens in a new tab)
  187. Yuen et al. (2025) (opens in a new tab)
  188. Yuen et al. (2026) (opens in a new tab)
  189. Zhou and Terrault (2020) (opens in a new tab)
  190. Zoulim et al. (2024) (opens in a new tab)